Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.900
+0.020 (1.06%)
At close: Apr 28, 2026, 4:00 PM EDT
1.950
+0.050 (2.63%)
Pre-market: Apr 29, 2026, 7:31 AM EDT
Acrivon Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 74 | 76 | 187 | 109 | 241 | - | |
| Market Cap Growth | 44.94% | -59.43% | 71.66% | -54.61% | - | - | |
| Enterprise Value | -42 | -50 | 4 | -28 | 291 | - | |
| Last Close Price | 1.90 | 2.41 | 6.02 | 4.92 | 11.52 | - | |
| PB Ratio | 0.53 | 0.68 | 1.06 | 0.90 | 1.41 | - | |
| P/TBV Ratio | 0.65 | 0.68 | 1.06 | 0.90 | 1.41 | - | |
| Debt / Equity Ratio | 0.02 | 0.02 | 0.02 | 0.04 | 0.03 | 0.06 | |
| Net Debt / Equity Ratio | -1.03 | -1.03 | -0.99 | -1.01 | -0.72 | -0.95 | |
| Net Debt / EBITDA Ratio | 1.40 | 1.40 | 1.99 | 1.85 | 3.80 | 5.82 | |
| Net Debt / FCF Ratio | 1.77 | 1.77 | 2.57 | 2.80 | 3.80 | 6.61 | |
| Quick Ratio | 7.57 | 7.57 | 10.43 | 9.58 | 19.61 | 34.18 | |
| Current Ratio | 7.69 | 7.69 | 10.55 | 9.75 | 20.27 | 34.46 | |
| Return on Equity (ROE) | -53.86% | -53.86% | -54.07% | -41.41% | -23.16% | -32.40% | |
| Return on Assets (ROA) | -32.22% | -32.22% | -33.30% | -26.25% | -14.18% | -18.60% | |
| Return on Capital Employed (ROCE) | -73.70% | -73.70% | -49.70% | -53.70% | -18.70% | -15.60% | |
| Earnings Yield | -105.83% | -102.44% | -42.98% | -55.30% | -12.95% | - | |
| FCF Yield | -88.75% | -85.91% | -36.51% | -40.23% | -13.42% | - | |
| Buyback Yield / Dilution | -13.96% | -13.96% | -53.05% | -435.63% | -136.43% | -21.70% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.